Numb and its alternative splicing in pancreatic cancer
10.3969/j.issn.1001-5256.2022.12.042
- VernacularTitle:Numb基因及其可变剪接在胰腺癌中的研究进展
- Author:
Penghao LI
1
;
Kailian ZHENG
1
;
Xiongfei XU
1
;
Gang JIN
1
Author Information
1. Department of Hepatobiliary Pancreatic and Splenic Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China
- Publication Type:Reviews
- Keywords:
Pancreatic Neoplasms;
Numb;
Spliceosomes
- From:
Journal of Clinical Hepatology
2022;38(12):2897-2900
- CountryChina
- Language:Chinese
-
Abstract:
Pancreatic cancer, a common digestive system tumor with high malignancy and a poor prognosis, has several treatment options. However, none of them are particularly effective because understanding the pathogenesis of pancreatic cancer remains a significant clinical challenge. Splicing isoforms mediate various biological phenotypes as an important means of regulating gene expression in eukaryotes, and their abnormalities can lead to a variety of diseases. Numb is an important cell fate determining protein whose alternative splicing has been linked to the development of various cancers. In pancreatic cancer, selective splicing of Numb can result in a variety of Numb protein subtypes, each with a different regulatory effect on the activation of various cancer-related signal pathways and tumor cell biology. This paper reviews the recent progress of Numb protein research in pancreatic cancer, with a focus on the regulatory role of its different isoforms in pathogenesis.
